Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Jan G J, van de Winkel"'
Autor:
Peter Boross, Stefan Lohse, Maaike Nederend, Johannes Hendrik Marco Jansen, Geert van Tetering, Michael Dechant, Matthias Peipp, Louise Royle, Li Phing Liew, Louis Boon, Nico van Rooijen, Wim K. Bleeker, Paul W. H. I. Parren, Jan G. J. van de Winkel, Thomas Valerius, Jeanette H. W. Leusen
Publikováno v:
EMBO Molecular Medicine, Vol 5, Iss 8, Pp 1213-1226 (2013)
Abstract Currently all approved anti‐cancer therapeutic monoclonal antibodies (mAbs) are of the IgG isotype, which rely on Fcgamma receptors (FcγRs) to recruit cellular effector functions. In vitro studies showed that targeting of FcαRI (CD89) by
Externí odkaz:
https://doaj.org/article/329d97c0f4a14fd1a47447646d3dc7c0
Autor:
Paul W. H. I. Parren, Marleen Voorhorst, Patrick J. Engelberts, Tom Vink, Frank J. Beurskens, Thomas Valerius, Wendy J.M. Mackus, Joost M. Bakker, Stefanie Derer, Tom van Meerten, Esther C.W. Breij, Janine Schuurman, Jan G. J. van de Winkel
Publikováno v:
Engelberts, P J, Voorhorst, M, Schuurman, J, Van Meerten, T, Bakker, J M, Vink, T, Mackus, W J M, Breij, E C W, Derer, S, Valerius, T, van de Winkel, J G J, Parren, P W H I & Beurskens, F J 2016, ' Type i CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells ', Journal of Immunology, vol. 197, no. 12, pp. 4829-4837 . https://doi.org/10.4049/jimmunol.1600811
Journal of Immunology, 197(12), 4829-4837. AMER ASSOC IMMUNOLOGISTS
Journal of Immunology, 197(12), 4829-4837. AMER ASSOC IMMUNOLOGISTS
Human IgG1 type I CD20 Abs, such as rituximab and ofatumumab (OFA), efficiently induce complement-dependent cytotoxicity (CDC) of CD20+ B cells by binding of C1 to hexamerized Fc domains. Unexpectedly, we found that type I CD20 Ab F(ab')2 fragments,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d9197ec28f899d5e6a016465f31efa
https://portal.findresearcher.sdu.dk/da/publications/34aca668-9af2-49ed-945c-3a69d108b381
https://portal.findresearcher.sdu.dk/da/publications/34aca668-9af2-49ed-945c-3a69d108b381
Autor:
Jan G. J. van de Winkel, Paul W. H. I. Parren, Daniela Hallack, Christian Kellner, Thomas Valerius, Tina Maurer, Martin Gramatzki, Matthias Peipp, Andreas Humpe, Roland Repp
Publikováno v:
The Journal of Immunology. 189:5037-5046
Induced self expression of the NKp30 ligand B7-H6 facilitates NK cell-mediated elimination of stressed cells. A fusion protein consisting of the ectodomain of B7-H6 and the CD20 single-chain fragment variable 7D8 was generated to mimic an induced sel
Autor:
Marjolein van Egmond, Marielle A. Otten, Jantine E. Bakema, Alison L. Tutt, Jan G. J. van de Winkel, Cornelis W. Tuk, Martin J. Glennie, R.H.J. Beelen
Publikováno v:
European Journal of Immunology. 42:1815-1821
Neutrophils potently kill tumour cells in the presence of anti-tumour antibodies in vitro. However, for in vivo targeting, the neutrophils need to extravasate from the circulation by passing through endothelial barriers. To study neutrophil migration
Autor:
Paul W. H. I. Parren, Ronald P. Taylor, Elizabeth M. Peek, Paul V. Beum, Frank J. Beurskens, Jan G. J. van de Winkel, Margaret A. Lindorfer, Patrick J. Engelberts
Publikováno v:
Journal of Immunology, 187(6), 3438-3447. AMER ASSOC IMMUNOLOGISTS
We previously reported that 1 h after infusion of CD20 mAb rituximab in patients with chronic lymphocytic leukemia (CLL), >80% of CD20 was removed from circulating B cells, and we replicated this finding, based on in vitro models. This reaction occur
Autor:
Stefan Loverix, Ignace Lasters, Janine Schuurman, Rebecca J. Rose, Aran F. Labrijn, Albert J. R. Heck, Paul W. H. I. Parren, Patrick Van Berkel, Ewald T. J. van den Bremer, Jan G. J. van de Winkel
Publikováno v:
Structure, 19(9), 1274-1282. CELL PRESS
Native mass spectrometry (MS) is a powerful technique for studying noncovalent protein-protein interactions. Here, native MS was employed to examine the noncovalent interactions involved in homodimerization of antibody half molecules (HL) in hinge-de
Autor:
Paul W. H. I. Parren, Thomas Valerius, Sven Berger, Jeroen J. Lammerts van Bueren, Katja Klausz, Michael Dechant, Matthias Peipp, Stefanie Derer, Jan G. J. van de Winkel, Stefan Lohse
Publikováno v:
Cancer Science. 102:1761-1768
Monoclonal antibodies (mAb) against variant III of epidermal growth factor receptor (EGFRvIII) hold promise for improving tumor selectivity of EGFR-targeted therapy. Here, we compared Fc-mediated effector functions of three mAb against EGFRvIII (MR1-
Autor:
Gosse J. Adema, Jan G. J. van de Winkel, Jantine E. Bakema, Paul J. Coffer, Jeanette H. W. Leusen, Marjolein van Egmond, Yvonne Kok, Simone de Haij, J. M. Bakker, Ida H. Hiemstra
Publikováno v:
European Journal of Immunology, 40(7), 2035-2040. Wiley-VCH Verlag
European Journal of Immunology, 40, 7, pp. 2035-40
Bakema, J E, Hiemstra, I H, Bakker, J, de Haij, S, Kok, Y, Adema, G, van Egmond, M, Coffer, PJ, Winkel, J G J & Leusen, J H W 2010, ' c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of Fc alpha RI and FcR gamma-chain ', European Journal of Immunology, vol. 40, no. 7, pp. 2035-2040 . https://doi.org/10.1002/eji.200939985
European Journal of Immunology, 40, 2035-40
European Journal of Immunology, 40, 7, pp. 2035-40
Bakema, J E, Hiemstra, I H, Bakker, J, de Haij, S, Kok, Y, Adema, G, van Egmond, M, Coffer, PJ, Winkel, J G J & Leusen, J H W 2010, ' c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of Fc alpha RI and FcR gamma-chain ', European Journal of Immunology, vol. 40, no. 7, pp. 2035-2040 . https://doi.org/10.1002/eji.200939985
European Journal of Immunology, 40, 2035-40
Contains fulltext : 87311.pdf (Publisher’s version ) (Closed access) The receptor for IgA, FcalphaRI or CD89, is expressed on myeloid cells and can trigger phagocytosis, tumor cell lysis, and release of inflammatory mediators. These functions criti
Autor:
Jantine E. Bakema, Paul W. H. I. Parren, Peter Boross, Frank J. Beurskens, J. H. Marco Jansen, Jeanette H. W. Leusen, Jan G. J. van de Winkel, Simone de Haij, Anton C.M. Martens, J. Sjef Verbeek, Desiree L Bos
Publikováno v:
Cancer Research. 70:3209-3217
Antibody–Fc receptor (FcR) interactions play an important role in the mechanism of action of most therapeutic antibodies against cancer. Effector cell activation through FcR triggering may induce tumor cell killing via antibody-dependent cellular c
Autor:
Paul V. Beum, Paul W. H. I. Parren, Frank J. Beurskens, Ronald P. Taylor, Margaret A. Lindorfer, Jan G. J. van de Winkel, Andrew W. Pawluczkowycz
Publikováno v:
The Journal of Immunology. 183:749-758
The CD20 mAb ofatumumab (OFA) is more effective than rituximab (RTX) in promoting complement-dependent cytotoxicity (CDC) of B cells via the classical pathway (CP) of complement. CP activation is initiated by C1q binding to cell-bound IgG. Therefore,